Skip to content

Impact of Virtual Reality on the Mental Health of Patients Undergoing Adjuvant Treatment for Colorectal Cancer

Impact of Virtual Reality on the Mental Health of Patients Undergoing Adjuvant Treatment for Colorectal Cancer VIRECAPS2

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05365256
Acronym
VIRECAPS2
Enrollment
98
Registered
2022-05-09
Start date
2022-04-15
Completion date
2025-04-30
Last updated
2022-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of Colon, Virtual Reality

Keywords

virtual reality, Colorectal cancer, Quality of life, Mental Health

Brief summary

The increase in the survival of cancer patients and the incidence of cancers leads to a rapid increase in the number of people living after a diagnosis of cancer. Occupation during chemotherapy treatment time has been identified as an excellent way to support cancer patients. Studies show that distraction interventions increase tolerance to treatment, by decreasing the importance given to negative stimuli associated with chemotherapy and increasing pleasurable emotions. In this context, virtual reality (VR) is a promising intervention for patients receiving chemotherapy. VR is considered a powerful painkiller, even more effective than other distractors, such as movies or video games for example. Several studies have shown short-term beneficial effects of integrating VR in patients undergoing chemotherapy. This intervention would help patients better adhere to and tolerate treatment. Considering that positive emotions could be one of the underlying processes necessary for the effectiveness of VR, it would be possible to support the cancer patient towards better overall well-being thanks to these new technologies. Investigators can therefore ask themselves the question of the impact that VR used during chemotherapy can have on the adaptation of patients to the disease and its treatments as well as on their psychological distress in the medium and long term.

Detailed description

The increase in the survival of cancer patients and the incidence of cancers leads to a rapid increase in the number of people living after a diagnosis of cancer. Supporting people during and after treatment is an element of the third Cancer Plan (2014-2019) promoting the emergence of innovations for the benefit of patients as well as the implementation of global and personalized actions of support, and wishing to reduce the impact of cancer on personal life. Occupation during chemotherapy treatment time has been identified as an excellent way to support cancer patients. Studies show that distraction interventions (progressive relaxation, guided imagery, cognitive distractions such as reading, humor, listening to music, watching a movie, etc.) increase tolerance to treatment, by decreasing the importance given to negative stimuli associated with chemotherapy and increasing pleasurable emotions. In this context, virtual reality (VR) is a promising intervention for patients receiving chemotherapy. It makes it possible to modulate the attentional and emotional processes responsible for physiological and psychic reactions (pain, psychological distress, anxiety). VR is considered a powerful painkiller, even more effective than other distractors, such as movies or video games for example. Several studies have shown short-term beneficial effects of integrating VR in patients undergoing chemotherapy. This intervention would help patients better adhere to and tolerate treatment. Considering that positive emotions could be one of the underlying processes necessary for the effectiveness of VR, it would be possible to support the cancer patient towards better overall well-being thanks to these new technologies. Investigators can therefore ask themselves the question of the impact that VR used during chemotherapy can have on the adaptation of patients to the disease and its treatments as well as on their psychological distress in the medium and long term.

Interventions

BEHAVIORALStandard distraction during chemotherapy treatment period

habitual distraction of patients during chemotherapy sessions authorized as part of routine care

BEHAVIORALVirtual distraction during chemotherapy treatment period

A virtual reality headset will be worn for 15 minutes per hour of treatment

Sponsors

GCS Ramsay Santé pour l'Enseignement et la Recherche
CollaboratorOTHER
Ramsay Générale de Santé
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female, over 18 years of age. * Patient with colorectal cancer treated with adjuvant chemotherapy. * Chemotherapy naïve patient * Patient speaking and understanding French and able to complete the questionnaires. * Affiliated patient or beneficiary of a social security scheme. * Patient having been informed of the research and having signed a free and informed consent

Exclusion criteria

* Patient participating in another clinical study * Patient with a history or progressive psychiatric illness * Patient with severe visual and hearing impairment * Patient not supporting the wearing of the virtual reality headset * Patient who is unable to undergo medical monitoring for geographical, social or psychological reasons * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * Pregnant, breastfeeding or parturient women

Design outcomes

Primary

MeasureTime frameDescription
Level of psychological well-being6 monthsTotal score from WEMWBS scale

Countries

France

Contacts

Primary ContactJF oudet
jf.oudet@ecten.eu683346567
Backup ContactMH BARBA
mh.barba@ecten.eu664888704

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026